Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The aim of this exploratory investigation was to determine if genetic variation within APP or its processing enzymes correlates with APP cleavage product levels: APPα, APPβ or Aβ42, in cerebrospinal fluid (CSF) of cognitively normal subjects or Alzheimer’s disease (AD) patients. Cognitively normal control subjects (n=170) and AD patients (n=92) were genotyped for 19 putative regulatory tagging SNPs within nine genes (APP, ADAM10, BACE1, BACE2, PSEN1, PSEN2, PEN2, NCSTN and APH1B) involved in the APP processing pathway. SNP genotypes were tested for their association with CSF APPα, APPβ, and Aβ42, AD risk and age-at-onset while taking into account age, gender, race and APOE ε4. After adjusting for multiple comparisons a significant association was found between ADAM10 SNP rs514049 and APPα levels. In controls, the rs514049 CC genotype had higher APPα levels than the CA,AA collapsed genotype, whereas the opposite effect was seen in AD patients. These results suggest that genetic variationwithin ADAM10, an APP processing gene, influences CSF APPα levels in an AD specific manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · cited 1×
“The majority of these mutations alter processing of APP so that the relative levels of Aβ42 are increased (Scheuner et al., 1996; Walker et al., 2005).”
Self-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731 · cited 2×
“Both soluble APP and Aβ are normally present in the brain and CSF (Seubert et al., 1992).”
Self-citationInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · cited 1×
“CSF Aβ42 levels are correlated with both AD status and Aβ deposition in the brain (Fagan et al., 2006; Tapiola et al., 2009; Visser et al., 2009).”
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · cited 3×
“…patients and controls have shown conflicting results (Diniz et al., 2008; Farlow et al., 1992; Galasko et al., 1998; Hampel et al., 2004; Hampel et al., 2008; Motter et al., 1995; Nakamura et al., 1994; Olsson et al., 2003; Palmert et al., 1990; Sunderland et al., 2004; Van Nostrand et al., 1992).”
Self-citationSunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656 · cited 1×
“CSF Aβ42 levels are significantly decreased in AD and mild cognitive impairment compared to controls (Galasko et al., 1998; Motter et al., 1995; Sunderland et al., 2003).”
Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614
Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584 · cited 1×
“Triplication of the APP gene, due to chromosome 21 trisomy in Down’s Syndrome, is associated with increased APP expression and amyloid plaque formation (Englund et al., 2007; Giaccone et al., 1989; Lemere et al., 1996).”
Gong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22831 · Cited by 442 · cited 1×
“(Gong et al., 2004; Ma et al., 2007) Molecular network analysis suggests aberrant CREB-mediated gene regulation in the AD hippocampus.”
Galasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Self-citationThe Disintegrin/Metalloproteinase ADAM10 Is Essential for the Establishment of the Brain Cortex
Jorissen, E., Prox, J., Bernreuther, C., Weber, S., Schwanbeck, R., Serneels, L., Snellinx, A., Craessaerts, K., Thathiah, A., Tesseur, I., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5221-09.2010 · Cited by 363 · cited 2×
“…recently it has been reported that an ADAM10 central nervous system conditional knockout has decreased APPα, APPβ and Aβ42 levels in the brain (Jorissen et al., 2010) suggesting that ADAM10 deficiency and the effects on APP processing may result in changes in cellular localization or…”
Hampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Dodel, R., Du, Y., Farlow, M., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001473 · Cited by 287 · cited 2×
“…in CSF but comparisons between AD patients and controls have shown conflicting results (Diniz et al., 2008; Farlow et al., 1992; Galasko et al., 1998; Hampel et al., 2004; Hampel et al., 2008; Motter et al., 1995; Nakamura et al., 1994; Olsson et al., 2003; Palmert et al., 1990; Sunderland et al.,…”
Self-citationKim, M., Suh, J., Romano, D., Truong, M. H., Mullin, K., Hooli, B., Norton, D., Tesco, G., Elliott, K., Wagner, S. L., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp323 · Cited by 234
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease
Zetterberg, H., Andreasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M. E., Buchhave, P., Londos, E., Umek, R. M., Minthon, L., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1102 · Cited by 224
Sunderland, T., Mirza, N., Putnam, K. T., Linker, G., Bhupali, D., Durham, R., Soares, H., Kimmel, L., Friedman, D., Bergeson, J., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.07.021 · Cited by 179
Peskind, E. R., Li, G., Shofer, J., Quinn, J. F., Kaye, J. A., Clark, C. M., Farlow, M. R., DeCarli, C., Raskind, M. A., Schellenberg, G. D., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.936 · Cited by 131 · cited 4×
“(Peskind et al., 2006)”
InfluentialSelf-citationGenomic structure and functional characterization of the human ADAM10 promoter
Prinzen, C., Müller, U., Endres, K., Fahrenholz, F., & Postina, R. (2005) · The FASEB Journal · doi:10.1096/fj.04-3619fje · Cited by 131 · cited 5×
“In addition, ADAM10 has been proposed as a potential AD therapeutic target because vitamin A has been reported to influence ADAM10 promoter activity (Prinzen et al., 2005) and acitretin, which is a synthetic retinoid drug, lowers Aβ peptide production and enhances APPα secretion in an AD mouse model.”
InfluentialEwers, M., Zhong, Z., Bürger, K., Wallin, A., Blennow, K., Teipel, S. J., Shen, Y., & Hampel, H. (2008) · Brain · doi:10.1093/brain/awn034 · Cited by 119 · cited 1×
“BACE1 has β-secretase activity and CSF BACE1 levels have been measured in AD compared to controls with contradicting results (Ewers et al., 2008; Wu et al., 2008; Zetterberg et al., 2008).”
Part-Time α-Secretases: The Functional Biology of ADAM 9, 10 and 17
Deuss, M., Reiss, K., & Hartmann, D. (2008) · Current Alzheimer Research · doi:10.2174/156720508783954686 · Cited by 98
Bekris, L. M., Millard, S. P., Galloway, N. M., Vuletic, S., Albers, J. J., Li, G., Galasko, D. R., DeCarli, C., Farlow, M. R., Clark, C. M., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13303 · Cited by 85
Self-citationExpression of the Anti-amyloidogenic Secretase ADAM10 Is Suppressed by Its 5′-Untranslated Region
Lammich, S., Buell, D., Zilow, S., Ludwig, A.-K., Nuscher, B., Lichtenthaler, S. F., Prinzen, C., Fahrenholz, F., & Haass, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.110742 · Cited by 48 · cited 2×
“(Lammich et al., 2010) Intriguingly, the rs514049 SNP is located within a predicted CREB/cJun transcription factor site at −644 (Prinzen et al., 2005) and is also located within a DNase hot spot (region of regulatory protein binding) reported by the ENCODE project, further implicating the…”
Cited by
Chen, Z., & Zhong, C. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.004 · Cited by 673
Duara, R., & Barker, W. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01185-z · Cited by 187
“It has been shown that among people without an APOE ε4 allele, a SNP (rs2075650) in the TOMM40 gene, which is closely associated with APOE, is associated with AD [22, 23], even after accounting for age and sex [24], thereby suggesting an APOE4-independent mechanism for TOMM40, which increases the risk for AD.”
BackgroundBourgade, K., Le Page, A., Bocti, C., Witkowski, J. M., Dupuis, G., Frost, E. H., & Fülöp, T. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150652 · Cited by 161
“The mechanism of A accumulation in LOAD is not fully understood but appears to be caused by overproduction or by a defect in clearance and degradation by microglial cells, or both [25].”
BackgroundPathophysiological function of ADAMTS enzymes on molecular mechanism of Alzheimer’s disease
Gurses, M. S., Ural, M. N., Gulec, M. A., Akyol, O., & Akyol, S. (2016) · Aging and disease · doi:10.14336/ad.2016.0111 · Cited by 35
“The effect of ADAM10 genetic variation on ADAM10 expression may help to better define the role of pathogenesis of AD, specific marker for the diagnosis of AD, and for treatment of AD [65, 73, 74].”
Background
Metadata
- Authors
- Bekris, L. M., Galloway, N. M., Millard, S., Lockhart, D., Li, G., Galasko, D. R., Farlow, M. R., Clark, C. M., Quinn, J. F., Kaye, J. A., Schellenberg, G. D., Leverenz, J. B., Seubert, P., Tsuang, D. W., Peskind, E. R., & Yu, C. E.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2011-03
- Volume
- 32
- Issue
- 3
- Pages
- 556.e13-556.e23
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2144457644
- Cited by
- 54
- References
- 22
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.